Additional Proxy Soliciting Materials (definitive) (defa14a)
2022年10月27日 - 6:20AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
14A
PROXY
STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
Filed
by the Registrant ☒
Filed
by a Party other than the Registrant ☐
Check
the appropriate box:
☐ |
Preliminary
Proxy Statement |
☐ |
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☐ |
Definitive
Proxy Statement |
☒ |
Definitive
Additional Materials |
☐ |
Soliciting
Materials Pursuant to §240.14a-12 |
MyMD
Pharmaceuticals, Inc.
(Name of Registrant as Specified in its Charter)
N/A
(Names of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment
of Filing Fee (check the appropriate box):
☒ |
No
fee required |
☐ |
Fee
paid previously with preliminary materials |
☐ |
Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 8 2024 まで 9 2024
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 9 2023 まで 9 2024
Real-Time news about Akers Biosciences Inc (ナスダック市場): 0 recent articles
その他のMymd Pharmaceuticals, Inc.ニュース記事